GeoVax Labs, Inc. Q1 FY2024 earnings call

• Clinical Developments: Advanced Gedeptin Phase I/II trial in head and neck cancer, expect final results in H1 2024; CM04S1 has 3 Phase II trials including healthy adult booster, immunocompromised, and CLL trials; MVA vaccine against Mpox and smallpox is in progress.
• Product Differentiation: Gedeptin is tumor-agnostic; CM04S1 is a next-gen COVID-19 vaccine with MVA platform effective for immunocompromised; MVA vaccine has potential for U.S. supply chain leadership.
• Partnerships and Collaborations: Actively pursuing partnerships for CM04S1, Gedeptin, and MVA; discussions on combination therapies and other solid tumor trials.

No detailed financial performance by product segments with absolute revenue and contribution % provided in the transcript.

• Expect to report final results from Gedeptin's Phase I/II trial and plans for expanded Phase II; results from CM04S1 Phase II programs; regulatory path for MVA vaccine; updates on MVA manufacturing process.
• Anticipate expedited registration paths for products.

• Uncertainty in development of competitive products.
• Ability to raise capital.
• Regulatory and manufacturing challenges.
• Dependence on external factors like partnerships and distributions.

Q: About Gedeptin's combination therapy and other options A: Focus on head and neck cancer initially, looking at other solid tumors like triple-negative breast cancer, early discussions with Emory and Oxford.

Q: About MVA vaccine milestones and revenues A: Progressing MVA with Oxford Biomedica, finalizing regulatory submissions, accelerated pathway, but no specific revenue timeline yet